-$0.23 EPS Expected for Health Catalyst (NASDAQ:HCAT) This Quarter

Equities research analysts expect Health Catalyst (NASDAQ:HCAT) to report earnings per share (EPS) of ($0.23) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Health Catalyst’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.21). Health Catalyst posted earnings of ($0.21) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 9.5%. The company is expected to report its next earnings report on Thursday, August 27th.

According to Zacks, analysts expect that Health Catalyst will report full year earnings of ($0.84) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.72). For the next financial year, analysts anticipate that the company will report earnings of ($0.62) per share, with EPS estimates ranging from ($0.89) to ($0.36). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Health Catalyst.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Tuesday, May 12th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. Health Catalyst had a positive return on equity of 30.42% and a negative net margin of 38.74%. The firm had revenue of $45.12 million for the quarter, compared to analysts’ expectations of $44.12 million. The firm’s revenue for the quarter was up 28.1% compared to the same quarter last year.

HCAT has been the topic of a number of analyst reports. Zacks Investment Research cut Health Catalyst from a “buy” rating to a “hold” rating in a research report on Tuesday. SVB Leerink lifted their price objective on Health Catalyst from $31.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. SunTrust Banks lifted their price objective on Health Catalyst from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Canaccord Genuity began coverage on Health Catalyst in a report on Thursday, April 2nd. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, ValuEngine upgraded Health Catalyst from a “hold” rating to a “buy” rating in a report on Tuesday, February 18th. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Health Catalyst presently has a consensus rating of “Buy” and a consensus price target of $40.33.

Shares of NASDAQ:HCAT remained flat at $$28.36 during trading on Friday. The stock had a trading volume of 422,389 shares, compared to its average volume of 824,448. Health Catalyst has a 52-week low of $17.48 and a 52-week high of $49.85. The company has a current ratio of 4.95, a quick ratio of 4.95 and a debt-to-equity ratio of 0.24. The stock has a market cap of $1.08 billion and a price-to-earnings ratio of -5.37. The stock has a fifty day simple moving average of $26.55 and a 200-day simple moving average of $31.16.

In other news, CTO Dale Sanders sold 27,500 shares of Health Catalyst stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $25.37, for a total transaction of $697,675.00. Following the sale, the chief technology officer now owns 176,412 shares of the company’s stock, valued at approximately $4,475,572.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Linda Llewelyn sold 1,121 shares of Health Catalyst stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $26.54, for a total transaction of $29,751.34. Following the sale, the insider now directly owns 26,498 shares in the company, valued at approximately $703,256.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 134,957 shares of company stock worth $3,623,758. Insiders own 22.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Clearbridge Investments LLC raised its position in shares of Health Catalyst by 120.4% during the 1st quarter. Clearbridge Investments LLC now owns 1,011,568 shares of the company’s stock valued at $26,453,000 after buying an additional 552,536 shares during the period. Perceptive Advisors LLC raised its position in shares of Health Catalyst by 15.9% during the 1st quarter. Perceptive Advisors LLC now owns 328,698 shares of the company’s stock valued at $8,375,000 after buying an additional 45,000 shares during the period. Capital International Investors raised its position in shares of Health Catalyst by 73.2% during the 1st quarter. Capital International Investors now owns 692,700 shares of the company’s stock valued at $18,114,000 after buying an additional 292,700 shares during the period. Tudor Investment Corp Et Al raised its position in shares of Health Catalyst by 9.1% during the 1st quarter. Tudor Investment Corp Et Al now owns 23,463 shares of the company’s stock valued at $614,000 after buying an additional 1,960 shares during the period. Finally, Schroder Investment Management Group raised its position in shares of Health Catalyst by 51.5% during the 1st quarter. Schroder Investment Management Group now owns 58,720 shares of the company’s stock valued at $1,631,000 after buying an additional 19,971 shares during the period. 64.09% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations primarily in the United States. The company operates through two segments, Technology and Professional services. Its products include cloud-based data platform, analytics software, and professional services.

Featured Article: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.